Catalyst Pharmaceuticals (CPRX) EBT Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.51% |
| Dec 31, 2025 | 52.48% |
| Sep 30, 2025 | 43.35% |
| Jun 30, 2025 | 46.15% |
| Mar 31, 2025 | 45.22% |
| Dec 31, 2024 | 54.58% |
| Sep 30, 2024 | 32.07% |
| Jun 30, 2024 | 37.36% |
| Mar 31, 2024 | 116.11% |
| Dec 31, 2023 | 39.17% |
| Sep 30, 2023 | -37.14% |
| Jun 30, 2023 | 58.91% |
| Mar 31, 2023 | 53.59% |
| Dec 31, 2022 | 52.05% |
| Sep 30, 2022 | 52.42% |
| Jun 30, 2022 | 56.14% |
| Mar 31, 2022 | 40.70% |
| Dec 31, 2021 | 38.40% |
| Sep 30, 2021 | 40.93% |
| Jun 30, 2021 | 40.53% |
| Mar 31, 2021 | 30.84% |
| Dec 31, 2020 | 28.48% |
| Sep 30, 2020 | 35.92% |
| Jun 30, 2020 | 33.75% |
| Mar 31, 2020 | 32.21% |
| Dec 31, 2019 | 34.54% |
| Sep 30, 2019 | 37.09% |
| Jun 30, 2019 | 40.97% |
| Mar 31, 2019 | 29.91% |
| Dec 31, 2018 | -60.66% |
| Sep 30, 2018 | -5.80% |
| Jun 30, 2018 | -13.67% |
| Mar 31, 2018 | -26.72% |
| Dec 31, 2017 | -134.13% |
| Sep 30, 2017 | -9.77% |
| Jun 30, 2017 | -68.10% |
| Mar 31, 2017 | -35.46% |
| Dec 31, 2016 | -12.10% |
| Sep 30, 2016 | -28.52% |
| Jun 30, 2016 | -26.79% |
| Mar 31, 2016 | -28.84% |
| Dec 31, 2015 | -51.49% |
| Sep 30, 2015 | -37.54% |